NEW YORK (GenomeWeb) — DNA testing firm PathogenDx announced today that it has closed a $3.4 million convertible note round.

The round was co-led by Altitude Investment Management and the Panther Opportunity Fund, with participation from CanopyVentures, Tendaji Investments, PB Venture Group, Salveo Capital, Halley Valley Venture, FlatIron Group, and Spearflower VC. Specific terms of the round were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.